Private Advisor Group LLC Purchases 1,957 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Private Advisor Group LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,276 shares of the biopharmaceutical company's stock after purchasing an additional 1,957 shares during the period. Private Advisor Group LLC's holdings in Regeneron Pharmaceuticals were worth $9,054,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Marietta Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the period. Pamalican Asset Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $4,915,000. Rhenman & Partners Asset Management AB raised its position in shares of Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after buying an additional 4,457 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research report on Monday, June 2nd. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Finally, Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Trading Down 1.4%

NASDAQ:REGN opened at $542.52 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company's 50-day simple moving average is $544.44 and its 200 day simple moving average is $613.61. The firm has a market capitalization of $58.57 billion, a P/E ratio of 13.81, a PEG ratio of 2.04 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm earned $9.55 EPS. The company's revenue was down 3.7% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.